33469-15-7

Usage

Uses

Since the specific applications of 2-(4-Chlorophenyl)-4-(trifluoromethyl)-1H-imidazole are not readily available in the common literature, the following uses are inferred based on the general properties of similar heteroaromatic compounds:
Used in Pharmaceutical Industry:
2-(4-Chlorophenyl)-4-(trifluoromethyl)-1H-imidazole may be used as a pharmaceutical intermediate for the synthesis of various drugs due to its unique chemical structure and potential biological activity.
Used in Agrochemical Industry:
2-(4-Chlorophenyl)-4-(trifluoromethyl)-1H-imidazole could also be utilized as an intermediate in the development of agrochemicals, such as pesticides or herbicides, given its potential to interact with biological systems.
Used in Material Science:
Due to its aromatic and azole nature, 2-(4-Chlorophenyl)-4-(trifluoromethyl)-1H-imidazole might be employed in the development of new materials with specific properties, such as in the synthesis of polymers or other organic materials with tailored characteristics.

InChI:InChI=1/C8H7BrFNO/c9-5-8(11-12)6-1-3-7(10)4-2-6/h1-4,12H,5H2/b11-8-

Upstream product

• 104-88-1 4-chlorobenzaldehyde 
• 431-67-4 1,1-dibromo-3,3,3-trifluoroacetone 

Downstream Products

• 34626-05-6 2-(4-chlorophenyl)-1H-imidazole-5-carboxylic acid 
• 1276122-55-4 2-(2-(4-chlorophenyl)-1H-imidazol-4-yl)benzo[d]oxazole-5-carbonitrile 
• 1276122-64-5 C₁₂H₁₀ClN₅S 
• 1276122-63-4 C₁₂H₁₀ClN₅S 
• 34626-05-6 2-(4-chlorophenyl)-4-carboxy-1H-imidazole 
• 279250-69-0 2-(4-chlorophenyl)-4-(N-methyl-N-methoxyaminocarbonyl)-1H-imidazole 
• 279251-15-9 2-(4-chlorophenyl)-1H-imidazole-4-carbaldehyde 

Relevant academic research and scientific papers

Discovery of novel 2-aryl-4-bis-amide imidazoles (ABAI) as anti-inflammatory agents for the treatment of inflammatory bowel diseases (IBD)

A series of 2-Aryl-4-Bis-amide Imidazoles (ABAI-1 to 30) were designed as anti-inflammatory agents. These compounds were synthesized and evaluated for the in vitro anti-inflammatory activities (inhibition of NO production and release of inflammatory cytok

BENZENESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF

The present disclosure provides compounds of Formula (I): and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled compounds, and prodrugs thereof. The provided compounds may be tumor necrosis factor ("TNF") receptor associated protein 1 ("TRAP1") modulators (e.g., TRAP1 activators). The provided compounds may also rescue the activity in PTEN-induced kinase 1 ("PINK1") loss of function contexts. The provided compounds may also improve mitochondrial health, function, quality, quantity, and/or activity, and/or reduce the production of reactive oxygen species. The provided compounds may also refold or solubilize aggregated or misfolded proteins such as α-synuclein. The present disclosure also provides pharmaceutical compositions comprising the provided compounds; kits comprising the provided compounds or pharmaceutical compositions; and methods of using the provided compounds and pharmaceutical compositions (e.g., for treating a disease in a subject in need thereof).

Synthesis, Antiviral Potency, in Vitro ADMET, and X-ray Structure of Potent CD4 Mimics as Entry Inhibitors That Target the Phe43 Cavity of HIV-1 gp120

In our attempt to optimize the lead HIV-1 entry antagonist, NBD-11021, we present in this study the rational design and synthesis of 60 new analogues and determination of their antiviral activity in a single-cycle and a multicycle infection assay to derive a comprehensive structure-activity relationship (SAR). Two of these compounds, NBD-14088 and NBD-14107, showed significant improvement in antiviral activity compared to the lead entry antagonist in a single-cycle assay against a large panel of Env-pseudotyped viruses. The X-ray structure of a similar compound, NBD-14010, confirmed the binding mode of the newly designed compounds. The in vitro ADMET profiles of these compounds are comparable to that of the most potent attachment inhibitor BMS-626529, a prodrug of which is currently undergoing phase III clinical trials. The systematic study presented here is expected to pave the way for improving the potency, toxicity, and ADMET profile of this series of compounds with the potential to be moved to the early preclinical development.

Synthesis, structure, and neuroprotective properties of novel imidazolyl nitrones

A new series of imidazolyl nitrones spin traps has been synthesized and evaluated pharmacologically. The salient structural feature of these molecules is the presence of an imidazole moiety substituted by aromatic or heteroaromatic cycles. This connectivi

Trifluoromethylimidazoles and a method for their preparation

4(5)-Trifluoromethylimidazoles having optional substituents in the 1 and 2 positions are provided. The novel 4(5)-trifluoromethylimidazoles are prepared by reacting a 1,1-dihalo-3,3,3-trifluoroacetone compound with an appropriate carboxaldehyde and ammoni

2-Pyrazinyl-trifluoromethylimidazoles and a method for their preparation

4(5)-Trifluoromethylimidazoles having optional substituents in the 1 and 2 positions are provided. The novel 4(5)-trifluoromethylimidazoles are prepared by reacting a 1,1-dihalo-3,3,3-trifluoroacetone compound with an appropriate carboxaldehyde and ammoni

4-Trifluoromethylimidazoles and 5-(4-pyridyl)-1,2,4-triazoles, new classes of xanthine oxidase inhibitors.

The syntheses of a number of 2-substituted 4-trifluoromethylimidazoles and 3-substituted 5-(4-pyridyl)-1,2,4-triazoles are described. The trifluoromethylimidazoles were prepared from 3,3-dibromo-1,1,1-trifluoroacetone after hydrolysis with aqueous sodium acetate solution and condensation with an aldehyde in the presence of ammonia. Basic hydrolysis of the trifluoromethyl group was found to provide a facile method for the synthesis of imidazole-4-carboxylic acids. In the imidazole series a 2-aryl substituent and a free imino group were required for xanthine oxidase inhibitory activity. The triazoles were obtained through the reaction of an aroylhydrazine and an imino ether followed by thermal ring closure of the intermediate acylamidrazone. As in the imidazole series, a free imino group is an absolute requirement for in vitro activity. Additional structure-activity relationships of these compounds are presented.